Approved Study Database
| Ref. No. | Scientific Title | Principal investigator |
|---|---|---|
| 2011.445 | Impact of a happiness-enhancing project on the level of happiness & perceived stress among psychiatric personnel | Ms LI SUK MAN |
| 2007.505 | The Molecular Epidemiology and Evolution of Heaptitis C Genotype 6a in Hong Kong | Dr Li Suet-Yee Cheryl |
| 2021.335 | Effectiveness of Home-based Family Caregiver-delivered Aromatherapy Programme for the Management of Behavioural and Psychological Symptoms of Dementia for Older Persons with Dementia |
Ms. LI Siu Yin 李小燕 |
| 2023.154 | Mitochondrial disease related mortality - evaluation of a large international cohort | Dr. LI Siu Hung |
| 2010.554 | A prospective study on reference values for normal motor and sensory nerves assessed by routine nerve conduction study among the Hong Kong Chinese | Dr. LI Siu Hung |
| 2023.370 | A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, for Stroke Prevention after an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack |
Dr. LI Siu Hung SIU HUNG LI |
| 2025.117 | The effects of transcranial direct current stimulation and cognitive behavioural programme on post-stroke fatigue | Dr LI SIU HUNG |
| 2017.613 | A Randomised, Double-Blind, Placebo-Controlled, International, Multicentre, Phase III Study to Investigate the Efficacy and Safety of Ticagrelor and ASA Compared with ASA in the Prevention of Stroke and Death in Patients with Acute Ischaemic Stroke or Transient Ischaemic Attack [THALES - Acute STroke or Transient IscHaemic Attack Treated with TicAgreLor and ASA for PrEvention of Stroke and Death] |
Dr. LI Siu Hung 李少雄 |
| 2018.311 | Retrospective study of mitochondrial disorder in Hong Kong |
Dr. LI Siu Hung 李少雄 |
| 2015.423 | Autoimmune encephalitis in Hong Kong : A retrospective study of clinical characteristics and outcomes |
Dr. LI Siu Hung 李少雄 |
| 2017.348 | Prevalence of neuromyelitis optica in Hong Kong |
Dr. LI Siu Hung 李少雄 |
| 2025.366 | A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of VRN110755 in Patients with Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC) | Dr LI Siu Ching Molly |
| 2025.339 | Lung Cancer Biomarker: Methylation Risk Score for Early Detection and Minimal Residual Disease Monitoring | Dr. LI Siu Ching |
| 2024.722 | Artificial intelligence as first-reader for lung cancer screening in high-risk non-smokers: a diagnostic validation study | Dr. LI Siu Ching |
| 2022.364 | Investigating the genomic landscape and evolution and its impact on clinical outcome in ALK-positive non-small cell lung cancer |
Dr. LI Siu Ching 李兆澄 |
| 2023.101 | Effect of IL24-expressing mesenchymal stem cells on immune system in lung cancer patients and health donors |
Dr. LI Siu Ching 李兆澄 |
| 2022.236 | Evaluation of Immune Tumour Microenvironment of EGFR mutation positive NSCLC after Osimertinib treatment |
Dr. LI Siu Ching 李兆澄 |
| 2023.099 | Neoadjuvant Sacituzumab Govitecan plus Pembrolizumab in Resectable Non-Small Cell Lung Cancer: an open-label, multicenter, single arm phase 2 study |
Dr. LI Siu Ching 李兆澄 |
| 2022.253 | Establishment of New Territories East Cluster Lung Cancer Database |
Dr. LI Siu Ching 李兆澄 |
| 2023.590 | A randomized controlled trial of an acceptance and commitment therapy-based parenting program for improving parenting stress and other health outcomes of parents and children with autism spectrum disorder |
Miss. LI Sini 李斯妮 |
| 2016.546 | Eye-hand Coordination, Visual Attention, and Physical Activity in Children with Cerebral Palsy |
Miss LI Ru 李如 |
| 2009.468 | Effect of a modified Tai Chi exercise on quality of life, anxiety and deprssion among stroke patients: a quasi-experimental study | Mr Li Pui On |
| 2016.419 | Low back pain self-management: evaluation of an intensive in-patient low back pain education program for female elderly with low back pain: A cohort study |
Miss LI Pui Man 李佩雯 |
| 2024.084 | Validation of the Chinese Fall Efficacy Scale (FES) | Ms. LI Pui Man |
| 2017.410 | The experience of patients and family caregivers in managing pneumoconiosis in the family context: An exploratory qualitative study | Prof. LI Polly Wai Chi |
| 2017.595 | Promoting brain health among people with suboptimal cognitive functioning in Hong Kong: A Brain Vitality Enhancement (BRAVE) program | Prof. LI Polly Wai Chi |
| 2019.086 | The effects of an empowerment-based cognitive behavioural therapy for insomnia on sleep, cognitive function and health-related quality of life in persons with mild cognitive impairment: A waitlist randomized controlled trial | Prof. LI Polly Wai Chi |
| 2018.430 | Psychometric evaluation of the Chinese version of the Atrial Fibrillation Effect on QualiTy-of-Life questionnaire and the Atrial Fibrillation Knowledge Scale | Prof. LI Polly Wai Chi |
| 2010.015 | Management of Diabetes Patients in a Primary CARE Setting - Health-Related Quality of Life and Anxiety Scores | Professor Li Philip Kam-tao |
| 2016.672 | Developing Gistful Thinking and Cognitive Flexibility among High-Functioning Adolescents with Autism Spectrum Disorder |
Mr. LI Philip Hung Kong 李鴻鋼 |
| 2011.051 | Evaluation of Quality of Care – Haemodialysis Public-Private-Partnership, HA | Prof. LI Philip |
| 2019.514 | EBBI, the key to excellent functional outcome in Chinese paediatric patients with lower extremity bone sarcoma | Dr . LI Moses Man Lung |
| 2023.149 | A Phase II, Open-label, Single-arm, Multi-centre Study to Evaluate the Safety and Efficacy of Osimertinib with Amivantamab as First-line Treatment in Participants with Epidermal Growth Factor Receptor Mutation-Positive, Locally Advanced or Metastatic Non-small Cell Lung Cancer (OSTARA) |
Dr. LI Molly Siu Ching 李兆澄 醫生 |
| 2022.571 | A Phase 2 Platform Study Evaluating the Safety and Efficacy of Novel Treatment Combinations in Patients With Lung Cancer (VELOCITY-Lung) Substudy-02: Patients With Disease Progression After Receiving Systemic Treatment for Non-Small-Cell Lung Cancer (NSCLC) |
Dr. LI Molly Siu Ching 李兆澄醫生 |
| 2022.392 | A Randomized, Open-Label, Phase 3 Study to Evaluate Zimberelimab and Domvanalimab in Combination with Chemotherapy Versus Pembrolizumab With Chemotherapy for the First-Line Treatment of Patients With Metastatic Non–Small Cell Lung Cancer With No Epidermal Growth Factor Receptor or Anaplastic Lymphoma Kinase Genomic Tumor Aberrations | Dr. LI Molly Siu Ching |
| 2025.302 | A Phase III, Open-label, Sponsor-blind, Randomized Study of Dato-DXd With or Without Osimertinib Versus Platinum-based Doublet Chemotherapy for Participants with EGFR-mutated Locally Advanced or Metastatic Non-small Cell Lung Cancer whose Disease has Progressed on Prior Osimertinib Treatment (TROPION-Lung15) | Dr. LI Molly Siu Ching |
| 2023.654 | An Open-Label, Phase 2b, Global Multicenter Cohort Trial to Assess the Safety and Efficacy of Zipalertinib in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Exon 20 Insertion and Uncommon/Single or Compound Epidermal Growth Factor Receptor Mutations | Dr. LI Molly Siu Ching |
| 2023.649 | A PHASE III, RANDOMIZED, DOUBLE-BLIND STUDY OF TIRAGOLUMAB PLUS ATEZOLIZUMAB COMPARED WITH PLACEBO PLUS ATEZOLIZUMAB IN PARTICIPANTS WITH COMPLETELY RESECTED STAGE IIB, IIIA, OR SELECT IIIB, PD-L1 POSITIVE, NON-SMALL CELL LUNG CANCER WHO HAVE RECEIVED ADJUVANT PLATINUM-BASED CHEMOTHERAPY | Dr. LI Molly Siu Ching |
| 2024.064 | A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Tarlatamab Therapy in Subjects With Limited-Stage Small-Cell Lung Cancer (LS-SCLC) who Have not Progressed Following Concurrent Chemoradiation Therapy (DeLLphi-306) | Dr. LI Molly Siu Ching |
| 2024.636 | A Phase 1/2 Open-Label, Multicenter, First-In-Human Study of the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of BH-30643 in Adult Subjects with Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations (SOLARA) | Dr. LI Molly Siu Ching |
| 2024.456 | A Phase 2, Open-Label, Single-Arm Study of Amivantamab and Lazertinib Combination Therapy as First-Line Treatment in Patients with EGFR-Mutated Recurrent Non-Small Cell Lung Cancer after Previous Treatment with Adjuvant Osimertinib in Early-Stage Disease | Dr. LI Molly Siu Ching |
| 2024.271 | A randomized, multicenter, double-blind, Phase 3 study to investigate the safety and efficacy of belrestotug in combination with dostarlimab compared with placebo in combination with pembrolizumab in participants with previously untreated, unresectable, locally advanced or metastatic PD-L1-selected non-small-cell lung cancer (GALAXIES LUNG-301) | Dr. LI Molly Siu Ching |
| 2024.230 | A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF DIVARASIB VERSUS SOTORASIB OR ADAGRASIB IN PATIENTS WITH PREVIOUSLY TREATED KRAS G12C-POSITIVE ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER | Dr. LI Molly Siu Ching |
| 2023.642 | LC-SHIELD (Lung Cancer Screening in HIgh risk nonsmokErs by artificial inteLligence Device) | Dr. LI Molly Siu Ching |
| 2025.459 | A PHASE III, RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF DIVARASIB AND PEMBROLIZUMAB VERSUS PEMBROLIZUMAB AND PEMETREXED AND CARBOPLATIN OR CISPLATIN IN PATIENTS WITH PREVIOUSLY UNTREATED, KRAS G12C-MUTATED, ADVANCED OR METASTATIC NON-SQUAMOUS NON−SMALL CELL LUNG CANCER | Dr. LI Molly Siu Ching |
| 2024.183 | A Phase 1b/2, multicenter, open-label platform study of select immunotherapy combinations in adult participants with previously untreated advanced non-small cell lung cancer (NSCLC) with high PD-L1 expression | Dr. LI Molly Siu Ching |
| 2024.174 | A Phase 2 Platform Study Evaluating the Safety and Efficacy of Novel Treatment Combinations in Patients With Lung Cancer (VELOCITY-Lung) Substudy-01: Patients With No Prior Systemic Treatment for Metastatic Non–Small-Cell Lung Cancer (mNSCLC) | Dr. LI Molly Siu Ching |
| 2024.171 | A Phase 3, Open-label, Multicenter, Randomized Study of Tarlatamab in Combination With Durvalumab vs Durvalumab Alone in Subjects with Extensive-Stage Small-Cell Lung Cancer Following Platinum, Etoposide and Durvalumab (DeLLphi-305) | Dr. LI Molly Siu Ching |
| 2022.338 | A Pilot Study in Development of Tissue Sparing Imaging with Virtual Immunohistochemical stain for Lung Cancer Diagnosis via Deep Learning |
Dr LI Molly 李兆澄 |
| 2019.374 | The effectiveness of WeChat couple-based psychosocial intervention (WCBPI) on sexual function, relationship satisfaction, dyadic coping and quality of life of gynaecological cancer patients and their partners: A mixed method study |
Ms. LI Minjie 李敏捷 |
Page 116 of 271.